Detection of TERT promoter mutations in primary adenocarcinoma of the urinary bladder

Morgan L. Cowan, Simeon Springer, Doreen Nguyen, Diana Taheri, Gunes Guner, Maria Angelica Mendoza Rodriguez, Yuxuan Wang, Isaac Kinde, Maria Del Carmen Rodriguez Pena, Christopher VandenBussche, Mathew T. Olson, Isabela Cunha, Kazutoshi Fujita, Dilek Ertoy, Kenneth W Kinzler, Trinity Bivalacqua, Nickolas Papadopoulos, Bert Vogelstein, George J. Netto

Research output: Contribution to journalArticle

Abstract

Summary TERT promoter mutations (TERT-mut) have been detected in 60% to 80% of urothelial carcinomas. A molecular urine-based screening assay for the detection of TERT-mut is currently being pursued by our group and others. A small but significant number of bladder carcinomas are adenocarcinoma. The current study assesses the incidence of TERT-mut in primary adenocarcinomas of urinary bladder. A retrospective search of our institutional pathology records identified 23 cystectomy specimens with a diagnosis of adenocarcinoma (2000-2014). All slides were reviewed by a senior urologic pathologist to confirm tumor type and select a representative formalin-fixed, paraffin-embedded block for mutational analysis. Adequate material for DNA testing was available in 14 cases (7 enteric type and 7 not otherwise specified). TERT-mut sequencing analysis was performed using previously described SafeSeq technique. Overall, 28.5% of primary adenocarcinoma harbored TERT-mut. Interestingly, 57% of nonenteric adenocarcinomas were mutation positive, whereas none of the enteric-type tumors harbored mutations. Similar to urothelial carcinoma, we found a relatively higher rate of TERT-mut among nonenteric-type adenocarcinomas further supporting the potential utility of TERT-mut urine-based screening assay for bladder cancer.

Original languageEnglish (US)
Pages (from-to)8-13
Number of pages6
JournalHuman Pathology
Volume53
DOIs
StatePublished - Jul 1 2016

Fingerprint

Urinary Bladder
Adenocarcinoma
Mutation
Carcinoma
Urine
Materials Testing
Cystectomy
Urinary Bladder Neoplasms
Paraffin
Formaldehyde
Neoplasms
Cohort Studies
Pathology
DNA

Keywords

  • Adenocarcinoma
  • Bladder carcinoma
  • Mutation
  • Telomerase
  • Telomerase reverse transcriptase
  • TERT

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Cowan, M. L., Springer, S., Nguyen, D., Taheri, D., Guner, G., Mendoza Rodriguez, M. A., ... Netto, G. J. (2016). Detection of TERT promoter mutations in primary adenocarcinoma of the urinary bladder. Human Pathology, 53, 8-13. https://doi.org/10.1016/j.humpath.2016.02.009

Detection of TERT promoter mutations in primary adenocarcinoma of the urinary bladder. / Cowan, Morgan L.; Springer, Simeon; Nguyen, Doreen; Taheri, Diana; Guner, Gunes; Mendoza Rodriguez, Maria Angelica; Wang, Yuxuan; Kinde, Isaac; Del Carmen Rodriguez Pena, Maria; VandenBussche, Christopher; Olson, Mathew T.; Cunha, Isabela; Fujita, Kazutoshi; Ertoy, Dilek; Kinzler, Kenneth W; Bivalacqua, Trinity; Papadopoulos, Nickolas; Vogelstein, Bert; Netto, George J.

In: Human Pathology, Vol. 53, 01.07.2016, p. 8-13.

Research output: Contribution to journalArticle

Cowan, ML, Springer, S, Nguyen, D, Taheri, D, Guner, G, Mendoza Rodriguez, MA, Wang, Y, Kinde, I, Del Carmen Rodriguez Pena, M, VandenBussche, C, Olson, MT, Cunha, I, Fujita, K, Ertoy, D, Kinzler, KW, Bivalacqua, T, Papadopoulos, N, Vogelstein, B & Netto, GJ 2016, 'Detection of TERT promoter mutations in primary adenocarcinoma of the urinary bladder', Human Pathology, vol. 53, pp. 8-13. https://doi.org/10.1016/j.humpath.2016.02.009
Cowan ML, Springer S, Nguyen D, Taheri D, Guner G, Mendoza Rodriguez MA et al. Detection of TERT promoter mutations in primary adenocarcinoma of the urinary bladder. Human Pathology. 2016 Jul 1;53:8-13. https://doi.org/10.1016/j.humpath.2016.02.009
Cowan, Morgan L. ; Springer, Simeon ; Nguyen, Doreen ; Taheri, Diana ; Guner, Gunes ; Mendoza Rodriguez, Maria Angelica ; Wang, Yuxuan ; Kinde, Isaac ; Del Carmen Rodriguez Pena, Maria ; VandenBussche, Christopher ; Olson, Mathew T. ; Cunha, Isabela ; Fujita, Kazutoshi ; Ertoy, Dilek ; Kinzler, Kenneth W ; Bivalacqua, Trinity ; Papadopoulos, Nickolas ; Vogelstein, Bert ; Netto, George J. / Detection of TERT promoter mutations in primary adenocarcinoma of the urinary bladder. In: Human Pathology. 2016 ; Vol. 53. pp. 8-13.
@article{522935ea558344dbb78120272396e647,
title = "Detection of TERT promoter mutations in primary adenocarcinoma of the urinary bladder",
abstract = "Summary TERT promoter mutations (TERT-mut) have been detected in 60{\%} to 80{\%} of urothelial carcinomas. A molecular urine-based screening assay for the detection of TERT-mut is currently being pursued by our group and others. A small but significant number of bladder carcinomas are adenocarcinoma. The current study assesses the incidence of TERT-mut in primary adenocarcinomas of urinary bladder. A retrospective search of our institutional pathology records identified 23 cystectomy specimens with a diagnosis of adenocarcinoma (2000-2014). All slides were reviewed by a senior urologic pathologist to confirm tumor type and select a representative formalin-fixed, paraffin-embedded block for mutational analysis. Adequate material for DNA testing was available in 14 cases (7 enteric type and 7 not otherwise specified). TERT-mut sequencing analysis was performed using previously described SafeSeq technique. Overall, 28.5{\%} of primary adenocarcinoma harbored TERT-mut. Interestingly, 57{\%} of nonenteric adenocarcinomas were mutation positive, whereas none of the enteric-type tumors harbored mutations. Similar to urothelial carcinoma, we found a relatively higher rate of TERT-mut among nonenteric-type adenocarcinomas further supporting the potential utility of TERT-mut urine-based screening assay for bladder cancer.",
keywords = "Adenocarcinoma, Bladder carcinoma, Mutation, Telomerase, Telomerase reverse transcriptase, TERT",
author = "Cowan, {Morgan L.} and Simeon Springer and Doreen Nguyen and Diana Taheri and Gunes Guner and {Mendoza Rodriguez}, {Maria Angelica} and Yuxuan Wang and Isaac Kinde and {Del Carmen Rodriguez Pena}, Maria and Christopher VandenBussche and Olson, {Mathew T.} and Isabela Cunha and Kazutoshi Fujita and Dilek Ertoy and Kinzler, {Kenneth W} and Trinity Bivalacqua and Nickolas Papadopoulos and Bert Vogelstein and Netto, {George J.}",
year = "2016",
month = "7",
day = "1",
doi = "10.1016/j.humpath.2016.02.009",
language = "English (US)",
volume = "53",
pages = "8--13",
journal = "Human Pathology",
issn = "0046-8177",
publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Detection of TERT promoter mutations in primary adenocarcinoma of the urinary bladder

AU - Cowan, Morgan L.

AU - Springer, Simeon

AU - Nguyen, Doreen

AU - Taheri, Diana

AU - Guner, Gunes

AU - Mendoza Rodriguez, Maria Angelica

AU - Wang, Yuxuan

AU - Kinde, Isaac

AU - Del Carmen Rodriguez Pena, Maria

AU - VandenBussche, Christopher

AU - Olson, Mathew T.

AU - Cunha, Isabela

AU - Fujita, Kazutoshi

AU - Ertoy, Dilek

AU - Kinzler, Kenneth W

AU - Bivalacqua, Trinity

AU - Papadopoulos, Nickolas

AU - Vogelstein, Bert

AU - Netto, George J.

PY - 2016/7/1

Y1 - 2016/7/1

N2 - Summary TERT promoter mutations (TERT-mut) have been detected in 60% to 80% of urothelial carcinomas. A molecular urine-based screening assay for the detection of TERT-mut is currently being pursued by our group and others. A small but significant number of bladder carcinomas are adenocarcinoma. The current study assesses the incidence of TERT-mut in primary adenocarcinomas of urinary bladder. A retrospective search of our institutional pathology records identified 23 cystectomy specimens with a diagnosis of adenocarcinoma (2000-2014). All slides were reviewed by a senior urologic pathologist to confirm tumor type and select a representative formalin-fixed, paraffin-embedded block for mutational analysis. Adequate material for DNA testing was available in 14 cases (7 enteric type and 7 not otherwise specified). TERT-mut sequencing analysis was performed using previously described SafeSeq technique. Overall, 28.5% of primary adenocarcinoma harbored TERT-mut. Interestingly, 57% of nonenteric adenocarcinomas were mutation positive, whereas none of the enteric-type tumors harbored mutations. Similar to urothelial carcinoma, we found a relatively higher rate of TERT-mut among nonenteric-type adenocarcinomas further supporting the potential utility of TERT-mut urine-based screening assay for bladder cancer.

AB - Summary TERT promoter mutations (TERT-mut) have been detected in 60% to 80% of urothelial carcinomas. A molecular urine-based screening assay for the detection of TERT-mut is currently being pursued by our group and others. A small but significant number of bladder carcinomas are adenocarcinoma. The current study assesses the incidence of TERT-mut in primary adenocarcinomas of urinary bladder. A retrospective search of our institutional pathology records identified 23 cystectomy specimens with a diagnosis of adenocarcinoma (2000-2014). All slides were reviewed by a senior urologic pathologist to confirm tumor type and select a representative formalin-fixed, paraffin-embedded block for mutational analysis. Adequate material for DNA testing was available in 14 cases (7 enteric type and 7 not otherwise specified). TERT-mut sequencing analysis was performed using previously described SafeSeq technique. Overall, 28.5% of primary adenocarcinoma harbored TERT-mut. Interestingly, 57% of nonenteric adenocarcinomas were mutation positive, whereas none of the enteric-type tumors harbored mutations. Similar to urothelial carcinoma, we found a relatively higher rate of TERT-mut among nonenteric-type adenocarcinomas further supporting the potential utility of TERT-mut urine-based screening assay for bladder cancer.

KW - Adenocarcinoma

KW - Bladder carcinoma

KW - Mutation

KW - Telomerase

KW - Telomerase reverse transcriptase

KW - TERT

UR - http://www.scopus.com/inward/record.url?scp=84963852977&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84963852977&partnerID=8YFLogxK

U2 - 10.1016/j.humpath.2016.02.009

DO - 10.1016/j.humpath.2016.02.009

M3 - Article

C2 - 26980028

AN - SCOPUS:84963852977

VL - 53

SP - 8

EP - 13

JO - Human Pathology

JF - Human Pathology

SN - 0046-8177

ER -